Erken Evre Küçük Hücreli Dışı Akciğer Kanserinde Hedefe Yönelik Tedaviler
Synopsis
Molecularly selected targeted therapies have become a core component of curative-intent multimodal treatment for early-stage non-small cell lung cancer (NSCLC). After complete resection, adjuvant osimertinib improved overall survival in patients with EGFR exon 19 deletion or L858R mutation, and adjuvant alectinib produced a marked disease-free survival benefit over chemotherapy in ALK-rearranged disease. More recently, ELEVATE demonstrated the efficacy of adjuvant ensartinib after chemotherapy, LIBRETTO-432 showed an event-free survival benefit with adjuvant selpercatinib in RET fusion-positive disease, and NeoADAURA established the superiority of neoadjuvant osimertinib-containing regimens for major pathological response. In unresectable stage III disease, LAURA showed that consolidation osimertinib after chemoradiotherapy markedly prolonged progression-free survival. These advances require molecular testing to be completed before perioperative treatment decisions rather than deferred until recurrence. This chapter reviews epidemiology, molecular diagnostics, the biology of driver subtypes and randomized evidence within a stage I, II and III framework, while preserving the original staging editions, control arms, endpoints and limits of generalizability of each trial. Stage-specific decision algorithms and comparative trial tables are provided. For ROS1, MET, BRAF, ERBB2, NTRK and KRAS alterations, efficacy in metastatic disease is distinguished from benefit proven in early-stage disease. Molecular residual disease, treatment duration, toxicity, resistance and surveillance are also discussed. Treatment selection should integrate anatomical risk, a validated predictive biomarker, appropriate comparative evidence and patient preferences. Key future questions are which patients need treatment intensification, in whom treatment can be safely de-escalated and how cure rates can be improved in rare molecular subgroups.
References
Tsuboi M, Herbst RS, John T, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. New England Journal of Medicine. 2023;389(2): 137–147. doi:10.1056/nejmoa2304594
Wu YL, Dziadziuszko R, Ahn JS, et al. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2024;390(14): 1265–1276. doi:10.1056/nejmoa2310532
Wu YL, Hochmair M, Yang Y, et al. Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2026;395(7): 660–670. doi:10.1056/nejmoa2602628
Zer A, Ahn MJ, Barlesi F, et al. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2025;36(11): 1245–1262. doi:10.1016/j.annonc.2025.08.003
Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2020;383(18): 1711–1723. doi:10.1056/nejmoa2027071
Yue D, Huang M, Song P, et al. Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2026;395(2): 151–161. doi:10.1056/nejmoa2518990
Dziadziuszko R, Solomon BJ, Wu YL, et al. 1787MO Updated Results From the Phase III ALINA Study of Adjuvant Alectinib vs Chemotherapy (Chemo) in Patients (Pts) With Early-Stage ALK+ Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology. 2025;36: S971–S972. doi:10.1016/j.annonc.2025.08.2413
Zhang C, Hu Y, Jiang BY, et al. Neoadjuvant Lorlatinib in Stage III NSCLC Harboring ALK Fusion: A Phase 2 Multicenter Study (LORIN). Journal of Clinical Oncology. 2026;44(16_suppl): 8002. doi:10.1200/jco.2026.44.16_suppl.8002
Wu YL, Majem M, John T, et al. Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial. Journal of Thoracic Oncology. 2026: 104179. doi:10.1016/j.jtho.2026.104179
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3): 229–263. doi:10.3322/caac.21834
Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Journal of Thoracic Oncology. 2018;13(3): 323–358. doi:10.1016/j.jtho.2017.12.001
Bossé Y, Boudreau DK, Saavedra Armero V, et al. Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project. Lung Cancer. 2025;203: 108530. doi:10.1016/j.lungcan.2025.108530
Soo RA, Reungwetwattana T, Perroud HA, et al. Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study. Journal of Thoracic Oncology. 2024;19(10): 1449–1459. doi:10.1016/j.jtho.2024.06.008
Pi C, Xu CR, Zhang MF, et al. EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China. Thoracic Cancer. 2018;9(7): 814–819. doi:10.1111/1759-7714.12651
Hondelink LM, Ernst SM, Atmodimedjo P, et al. Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy. European Journal of Cancer. 2023;181: 53–61. doi:10.1016/j.ejca.2022.12.010
Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. Journal of Clinical Oncology. 2022;40(6): 611–625. doi:10.1200/jco.21.01626
Olmedo ME, Cervera R, Cabezon-Gutierrez L, et al. New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2. World Journal of Clinical Oncology. 2022;13(4): 276–286. doi:10.5306/wjco.v13.i4.276
Abbosh C, Frankell AM, Harrison T, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023;616(7957): 553–562. doi:10.1038/s41586-023-05776-4
Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discovery. 2017;7(12): 1394–1403. doi:10.1158/2159-8290.cd-17-0716
Blakely CM, Urisman A, Gubens MA, et al. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study. Journal of Clinical Oncology. 2024;42(26): 3105–3114. doi:10.1200/jco.24.00071
Herbst RS, John T, Grohé C, et al. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nature Medicine. 2025;31(6): 1958–1968. doi:10.1038/s41591-025-03577-y
Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2024;390(2): 118–131. doi:10.1056/nejmoa2302299
Zhou C, Solomon B, Loong HH, et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. New England Journal of Medicine. 2023;389(20): 1839–1850. doi:10.1056/nejmoa2309457
Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. New England Journal of Medicine. 2021;384(25): 2371–2381. doi:10.1056/nejmoa2103695
Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. New England Journal of Medicine. 2022;387(2): 120–131. doi:10.1056/nejmoa2204619
Wolf J, Seto T, Han JY, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2020;383(10): 944–957. doi:10.1056/nejmoa2002787
Planchard D, Smit EF, Groen HJM, et al. Dabrafenib Plus Trametinib in Patients With Previously Untreated BRAFV600E-mutant Metastatic Non-Small-Cell Lung Cancer: An Open-Label, Phase 2 Trial. The Lancet Oncology. 2017;18(10): 1307–1316. doi:10.1016/s1470-2045(17)30679-4
Li BT, Smit EF, Goto Y, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2022;386(3): 241–251. doi:10.1056/nejmoa2112431
Ghazali N, Feng J, Hueniken K, et al. Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241308466
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 9.2026. 2026. (28/09/2026 tarihinde https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf adresinden ulaşılmıştır).
Herbst RS, Wu YL, John T, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. Journal of Clinical Oncology. 2023;41(10): 1830–1840. doi:10.1200/jco.22.02186
Tsutani Y, Goldman JW, Dacic S, et al. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2. Clinical Lung Cancer. 2023;24(4): 376–380. doi:10.1016/j.cllc.2023.02.002
ClinicalTrials.gov. A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection (NCT05120349). 2026. (28/09/2026 tarihinde https://clinicaltrials.gov/study/NCT05120349 adresinden ulaşılmıştır).
Pisters K, Kris MG, Gaspar LE, et al. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology. 2022;40(10): 1127–1129. doi:10.1200/JCO.22.00051
Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. Journal of Clinical Oncology. 2008;26(21): 3552–3559. doi:10.1200/jco.2007.13.9030
Singh N, Daly ME, Ismaila N, et al. Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology. 2023;41(27): 4430–4432. doi:10.1200/JCO.23.01261
He J, Tsuboi M, Weder W, et al. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. Journal of Clinical Oncology. 2025;43(26): 2875–2887. doi:10.1200/jco-25-00883
Puri S, Leighl NB, Ismaila N, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0. Journal of Clinical Oncology. 2026;44(7). doi:10.1200/jco-25-02822
Travis WD, Dacic S, Wistuba I, et al. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology. 2020;15(5): 709–740. doi:10.1016/j.jtho.2020.01.005
Zhong WZ, Yan HH, Chen KN, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal Transduction and Targeted Therapy. 2023;8(1). doi:10.1038/s41392-022-01286-3
Lu S, Kato T, Dong X, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. New England Journal of Medicine. 2024;391(7): 585–597. doi:10.1056/nejmoa2402614
Daly ME, Singh N, Ismaila N, et al. Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology. 2024;42(25): 3058–3060. doi:10.1200/JCO-24-01324
Yu J, Meng X, Ge H, et al. PL04.13 Aumolertinib Maintenance after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer: Interim Results of the Phase III Study (POLESTAR). Journal of Thoracic Oncology. 2024;19(10): S6–S7. doi:10.1016/j.jtho.2024.09.021
Bi N, Wang J, Jiang W, et al. Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation. Signal Transduction and Targeted Therapy. 2026;11(1): 395. doi:10.1038/s41392-026-02891-2
Goss GD, O'Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. Journal of Clinical Oncology. 2013;31(27): 3320–3326. doi:10.1200/jco.2013.51.1816
Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology. 2015;33(34): 4007–4014. doi:10.1200/jco.2015.61.8918
Pennell NA, Neal JW, Chaft JE, et al. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 2019;37(2): 97–104. doi:10.1200/jco.18.00131
Zhong WZ, Wang Q, Mao WM, et al. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. Journal of Clinical Oncology. 2021;39(7): 713–722. doi:10.1200/jco.20.01820
Yue D, Xu S, Wang Q, et al. Erlotinib Versus Vinorelbine Plus Cisplatin as Adjuvant Therapy in Chinese Patients With Stage IIIA EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EVAN): A Randomised, Open-Label, Phase 2 Trial. The Lancet Respiratory Medicine. 2018;6(11): 863–873. doi:10.1016/s2213-2600(18)30277-7
He J, Su C, Liang W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. The Lancet Respiratory Medicine. 2021;9(9): 1021–1029. doi:10.1016/s2213-2600(21)00134-x
Tada H, Mitsudomi T, Misumi T, et al. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT). Journal of Clinical Oncology. 2022;40(3): 231–241. doi:10.1200/jco.21.01729
ClinicalTrials.gov. A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (NCT05526755). 2026. (28/09/2026 tarihinde https://clinicaltrials.gov/study/NCT05526755 adresinden ulaşılmıştır).
Osarogiagbon RU, Cetnar JP, Aljumaily R. Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer. American Society of Clinical Oncology Educational Book. 2026;46(3). doi:10.1200/edbk-26-518244
Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. New England Journal of Medicine. 2023;389(22): 2039–2051. doi:10.1056/nejmoa2306441
US Food and Drug Administration. Alecensa prescribing information. 2024. (28/09/2026 tarihinde https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf adresinden ulaşılmıştır).
Leonetti A, Boni L, Gnetti L, et al. Alectinib as Neoadjuvant Treatment in Potentially Resectable Stage III ALK-positive NSCLC: Final Analysis of ALNEO Phase II Trial (GOIRC-01-2020-ML42316). Journal of Clinical Oncology. 2025;43(16_suppl): 8015. doi:10.1200/jco.2025.43.16_suppl.8015
ClinicalTrials.gov. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) (NCT04302025). 2026. (28/09/2026 tarihinde https://clinicaltrials.gov/study/NCT04302025 adresinden ulaşılmıştır).
Paik PK, Felip E, Veillon R, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. New England Journal of Medicine. 2020;383(10): 931–943. doi:10.1056/nejmoa2004407
ClinicalTrials.gov. Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC (NCT04926831). 2025. (28/09/2026 tarihinde https://clinicaltrials.gov/study/NCT04926831 adresinden ulaşılmıştır).
Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. New England Journal of Medicine. 2018;378(8): 731–739. doi:10.1056/nejmoa1714448
Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Annals of Oncology. 2019;30(5): 839–844. doi:10.1093/annonc/mdz077
Gerber DE, Oxnard GR, Govindan R. ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer. Clinical Pharmacology & Therapeutics. 2015;97(5): 447–450. doi:10.1002/cpt.91
ClinicalTrials.gov. To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (NCT04853342). 2026. (28/09/2026 tarihinde https://clinicaltrials.gov/study/NCT04853342 adresinden ulaşılmıştır).
ClinicalTrials.gov. Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations (NCT04687241). 2024. (28/09/2026 tarihinde https://clinicaltrials.gov/study/NCT04687241 adresinden ulaşılmıştır).
Matsumura Y, Yoh K, Zenke Y, et al. Initial Results of a Screening Trial for Evaluating Oncogenic Drivers in Japanese Patients With Surgically Resected Early-Stage Non-Small Cell Lung Cancer: LC-SCRUM-Advantage. Journal of Clinical Oncology. 2025;43(16_suppl): 8065. doi:10.1200/jco.2025.43.16_suppl.8065